PIR and Miyoshi myopathy: The ability of G-MDSCs to retain stemness diminished when silencing piR-823 in MM cells, which reduced tumor growth and angiogenesis in vivo, implying that piR-823 might be a unique anti-cancer therapy that targets both G-MDSCs and CSCs in the MM microenvironment (Ai et al. 2019).